{"id":815869,"date":"2025-02-20T16:15:18","date_gmt":"2025-02-20T21:15:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/"},"modified":"2025-02-20T16:15:18","modified_gmt":"2025-02-20T21:15:18","slug":"artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/","title":{"rendered":"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, Feb.  20, 2025  (GLOBE NEWSWIRE) &#8212; Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45<sup>th<\/sup> Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA.<\/p>\n<p>Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference.<\/p>\n<p>Investors and the general public are invited to listen to a live webcast of the presentation through the &#8220;Investors&#8221; section on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jcu_OpS8G_B_FAvR6kAf5oSXHJtj7sy6lKLIWDTTSoRmlv7QvEdLSuZtr4xkyHjHzZs6RsvbqtlZ5ybx3vewhj-hz4Ucc0vrpgAH9D98rFG03oVd6jcRILBsVQ-tKBo_X4K2aNGHZoACQgTH2cRJln6DZLktw5HnPfwUAg94e4_TRcYcWaSPbZ6b-CSKgI6zhltefNhgpoJFKS-zbmv-r8cDXfeLvNKWsti8BcwmATVhs0MXi0tN8jXghj1e3RbaFbukZvbl2nKlVitYrDoft5wLi7jAAk6aLZcHn-62vk3X7pmnL8P_ui5G1Q0Xs1F54IIsnUCbiHGFtSSB7d9P55HV0l-FsSbbLeqUcIypYAYpvykbGNQicTcjOC0f9NKvKCRc-WA9FQYyMy-S_XVa3MeUZg-Y-AL3JPl1n42YPv9F4aqitKtF44cVFonL1ZrGFEAOXYtoZjuM5g3Y492P1-8brw-TRM6xy0z1aiv6p6M=\" rel=\"nofollow\" target=\"_blank\"><strong>Artivabio.com<\/strong><\/a>. A webcast replay will be made available following the event for 90 days.<\/p>\n<p>\n        <strong>About Artiva Biotherapeutics<\/strong>\n      <\/p>\n<p>Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva\u2019s lead program, AlloNK<sup>\u00ae<\/sup>, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK<sup>\u00ae<\/sup>\u00a0is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva\u2019s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell\u2019s NK cell manufacturing technology and programs.\u00a0<\/p>\n<p>Artiva is headquartered in San Diego, California. For more information, please visit<strong>\u00a0<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pOxk8t7cPuFSKVvjT1_YkCBalwOAAwhFnMjzsMoOMjxZknJinqKmgFx24pMj8vAEezmx9hZg5DTOzAV5TotOW7YQsv9rmx8UlFluLmYsFAA=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.artivabio.com\/<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.\u2019s (the \u201cCompany\u201d) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company\u2019s actual results to differ from current expectations are discussed in the Company\u2019s filings with the Securities and Exchange Commission (the \u201cSEC\u201d), including the section titled \u201cRisk Factors\u201d in the Company\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Investors: Neha Krishnamohan,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jcu_OpS8G_B_FAvR6kAf5s71CDLCD5rTAgfDZ1aRadXbSwG9YYnlVfQh4VPCd6I8ZII0cWzyThTk3rN2afi_gp2lTbqoD8Cj5jX_9ATL4GNEnrFNauYIxaNXihfPAXV0L2GiULIUb1UCsihZdFrcqF76RtgvpkwcNJxx_CjAAWr1t5zJYfYZhK4R8Lh6KzoqGmvWfiyELdSNRkvzU5ofneREAVmSYAFR2uzDz9ij4q6vf_0AfQkVes0ga6cM82-lMZY7uyqaWouhY8whvvaZsXt6IkXBGs2nT-QkAKsCKqs7FlsVz9VVFVZ-QS7rBUD75x5JRO3gvtZaeoshFiEAo56q-vpT27NodbXKakxLLCPPgSLgnzyqSEa3i_SjQ6L9IBqEB8jw5ONwi4d9wwO1TyZjsSzVeRCU1jgjniqOzH7bJW-5wevDXnpaIORuRawR-xyZDhP-yT3BNQcvjy1yqVm_4mVDPYffnKwls9Z7cTwlCO6jL5I0JkoZ3Dz3fqQ6\" rel=\"nofollow\" target=\"_blank\">Artiva Biotherapeutics<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pfnJ16LA-DVQOWvgznXPUG_tPMjpeetVmzg8wCc65aKMwNgp4bGCZrN7qtZleRJRXSjDa_MMd1AEUu81CFa1Lxx9YOmSWXRZY8a9-TuGeHceGEkcTf4O1iOXOXLdpdox9mNIv3fHKAveica-nd_KCB7_lGIFKISXaidwDbmaykJC3JT-nvL4zvh1JYQvHIACfr0nlvhBJEQlHIJ6BqZ4lIU9UtqAMc-n2H26gjRmsHCr9tlB0b42ChMKHQw5FLx-ukJ6J7ydPnAHmxcOqDmaunmhntJhSteox3hxKEoVhMeugRaI2wJcGV153a21qqjdBSzyAueUKhJ-eF7vpkSCCc8UXObkZk1PEXWy0ClNiVumdkpaYWYQOfuss-oJG7uZcuTVwvESHjJcDP2qBvJCF9s3nepmC4pkJSbwB9Axh-E=\" rel=\"nofollow\" target=\"_blank\">ir@artivabio.com<\/a><br \/>Media: Jessica Yingling, Ph.D.,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3I4-YUVh_oMX7hxeoFjTxzcmcAzEmQuEYFLh_09y2urJ7RRcWbZnMnVK9ZEiNLGJzoPWOT9JdDISQwSkXsA46Xgs-I4VmTc40pg0fTu4uVSYWVxmkTq3yIGQ-aIVLZOH7ezPhL45Q353rUoJSFzXK5f79m_dhBuq2yU6bIEp9nMgWy931UmTRPR_XbKAc3jSN_X8kQKxmEtAXSZ2SIt_NQaV0CCXR15GmVVjiNYn6WoTuTmonzU4ccdXneVu9zGIDpYZ7YAz6hmjvCJftDjv4o7vHJY-8F7Kz2uc_H0c5iLJY5T-G4mqimfAHco5k8I8J1IseNMoBsQ9x45hWvq6BRwiQygdIpm9c-zFf7LCyhKdF46XtraujAegeX9_NYgad-3BLk1tS5LJTeaT76qhvsSGIBOrejsuV0wpY3KV1jSeEkvNzPrgGvQnCdskNEIWRbcyjocs_n1E0ahCGhwwfWMy-wiFCd9yfsCPTFnKeHgHGnIDy8SxJv7mbTfikkhP\" rel=\"nofollow\" target=\"_blank\">Little Dog Communications Inc.<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PDfNRfkrTM2zRC6mI6YhLvZXtfHBy0A-miuXNZOAM4LnQvnecWGVzbAqWiyAMUy7RTimACZi-tFMmtZ714-bRqj5Jn-9MpSjDWtRmVqPMkDRiWOb97Q_mt3WiQ6wSJgXleYoEz_kIgjXaVIdU4hds3AHy29Wnbl3XZ8_IWUgJXo6fNjqv3yXDF3mbYHHnWhOXajltagb4fK1_IPgsyLdUNqIrkjEwg1J9Vx1QMTEqEoYvBEBjEdVC-noo4BkNK2Ffww1hCJFNX71H-LoPm3nVS-_l-aLYoxzGvc3_Bn1Quy-GMO1OTo8Jrwvp8auz2JH0drG-3dmZ0tn4bg9x_H8KLa3_AgBIa7JYaGwnxLrJt8lPDfqFoew_oJC6611czR305lk1lpu4u7KQpK8KUJrNiMjluFM8S6CDyJuW9Jyp7SyE2br2RYgfycELLsLP1LfUEWe7NGtTGc0Y_es0guqDkRhcv9s1EObLlP6Mp8yETo=\" rel=\"nofollow\" target=\"_blank\">jessica@litldog.com<\/a>, <br \/>+1.858.344.8091<\/p>\n<p>Source: Artiva Biotherapeutics, Inc.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MWU4ZDAwNzEtNDJhMi00Njk4LTg2ZWItYTU3YWVlYmUwMmQ0LTEzMDM0NTE=\/tiny\/Artiva-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the &#8220;Investors&#8221; section on\u00a0Artivabio.com. A webcast replay will be made available following the event for &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-815869","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the &#8220;Investors&#8221; section on\u00a0Artivabio.com. A webcast replay will be made available following the event for &hellip; Continue reading &quot;Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-20T21:15:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference\",\"datePublished\":\"2025-02-20T21:15:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/\"},\"wordCount\":554,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/\",\"name\":\"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=\",\"datePublished\":\"2025-02-20T21:15:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/","og_locale":"en_US","og_type":"article","og_title":"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Market Newsdesk","og_description":"SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) &#8212; Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA. Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen to a live webcast of the presentation through the &#8220;Investors&#8221; section on\u00a0Artivabio.com. A webcast replay will be made available following the event for &hellip; Continue reading \"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-20T21:15:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference","datePublished":"2025-02-20T21:15:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/"},"wordCount":554,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/","name":"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=","datePublished":"2025-02-20T21:15:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM2MDI0OSM2NzU2MjA5IzIyOTE5MDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/artiva-biotherapeutics-to-participate-in-the-td-cowen-45th-annual-health-care-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=815869"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/815869\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=815869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=815869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=815869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}